research Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
Search
for
Sort by
Research
60-90 / 1000+ results 
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Human Metapneumovirus (HMPV): Gambaran Klinis dan Tata Laksana
HMPV causes respiratory infections, mainly managed with supportive care, and lacks a vaccine or specific treatment.
research Clobetasol/minoxidil
research The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
Cepharanthine shows promise as a COVID-19 treatment.
research Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
research Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine could be a strong antiviral against COVID-19.
research TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic
A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.
research Evaluation of the Relationship between Favipiravir Use Status and Telogen Effluvium in Patients Diagnosed with COVID-19
Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
research Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research A skin organoid-based infection platform identifies an inhibitor specific for HFMD
NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
research Anticoronavirus Isoquinoline Alkaloids: Unraveling the Secrets of Their Structure–Activity Relationship
Certain alkaloids could help create new coronavirus drugs.
research Antiviral effects of human placenta hydrolysate (Laennec®) against SARS-CoV-2 in vitro and in the ferret model
Human placenta hydrolysate may help treat COVID-19 by reducing virus replication and boosting immune response.
research TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target
TMPRSS2 is crucial for COVID-19 infection and is a potential target for treatment.
research Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
A new method using human lung cells helps find drugs to block and reduce inflammation from SARS-CoV-2.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research LSO-072 Comparison of COVID-19 vaccination with influenza vaccination in Korean patients with systemic lupus erythematosus: perception, adverse events, and flares from the CIVIL study
The COVID-19 vaccine is viewed more negatively and causes more side effects than the flu vaccine in Korean patients with lupus.
research Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
research A Reappraisal of the Antiviral Properties of and Immune Regulation through Dietary Phytochemicals
Plant compounds may boost antiviral treatments.
research Nitroxide pharmaceutical development for age-related degeneration and disease
Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
research Severe Acute Respiratory Syndrome (SARS)
The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
research Latanoprost
research Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Finasteride Induces Epigenetic Alteration of TMPRss2 Gene Expression: A Potential role in Severe Acute Respiratory Syndrome-Corona Virus-2 Inhibition
Finasteride may help reduce COVID-19 infection by altering a key gene.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children
Children generally have milder SARS symptoms than adults, with good outcomes and no deaths reported, but long-term effects are unclear.